摘要
目的观察两种聚乙二醇干扰素(PEG-INF)联合利巴韦林治疗慢性丙型肝炎的临床疗效。方法回顾分析澳门仁伯爵综合医院171例慢性丙型肝炎患者的临床资料,其中基因1b型145例,基因6a型26例。140例患者采用聚乙二醇干扰素α-2b注射剂(PEG-IFN-2b)与利巴韦林联合治疗,31例采用聚乙二醇干扰素α-2a注射液(PEG-IFN-2a)与利巴韦林联合治疗,总疗程48周,分别于治疗12、24、48周及治疗结束后24周评价病毒学疗效。结果所有患者均完成治疗,总早期病毒应答率(EVR)为78.95%,持续病毒学应答率(SVR)为69.59%。两组患者在EVR(P=0.091)、治疗结束时病毒学应答率(ETVR)(P=0.542)、SVR(P=0.079)和复发率(P=0.497)方面差异均无统计学意义。两种基因型患者的EVR(P=0.268)、ETVR(P=0.276)、SVR(P=0.479)和复发率(P=1.000)间差异也均无统计学意义。结论两种PEG-INF联合利巴韦林治疗慢性丙型肝炎均有较高应答率且疗效相当,对两种HCV基因型患者的疗效也无明显差异。
Objective To explore the effectiveness of a combined therapy using two types of peginterferon(PEG-IFN) and ribavirin in treating chronic hepatitis C virus(HCV) genotypes 1b/6a infections.Methods The clinical data of 171 patients with chronic HCV genotypes 1b/6a infection in Common Hospital Centre S.Januario,Macao SAR,China,were retrospectively analyzed.Of these patients,145(84.8%) were infected with HCV genotype 1b and 26(15.2%) with HCV genotype 6a.Patients were divided into two groups based on drug therapies: PEG-IFN-2b group(n=140),in which patients were treated with PEG-IFN-2b 1.5 g/kg QW plus ribavirin 800-1 200 mg/d and PEG-IFN-2a group(n=31),in which patients were treated with PEG-IFN-2a 180g QW plus ribavirin 800-1200mg/d.Patients was treated for 48 weeks and then followed up for 24 weeks.Results All patients completed their therapies.The rates of early viral response(EVR) and sustained virologic response(SVR) were 78.95% and 69.59%,respectively.The two groups were not significantly different in terms of EVR(P=0.091),end of treatment virological response(ETVR)(P=0.542),SVR(P=0.079),relapse(P=0.497).And the two HCV genotypes patients were not significantly different in terms of EVR(P=0.268),ETVR(P=0.276),SVR(P=0.479),and relapse(P=1.000).Conclusions PEG-IFN combined with ribavirin can achieve high viral response in treating chronic hepatitis C.PEG-IFN-2a and PEG-IFN-2b basically are similarly effective in treating HCV genotype 1b or 6a infections.
出处
《中国医学科学院学报》
CAS
CSCD
北大核心
2010年第3期320-323,共4页
Acta Academiae Medicinae Sinicae
